Zoetis reports Q4 adjusted EPS $1.24, consensus $1.32

Reports Q4 revenue $2.21B, consensus $2.19B. “Zoetis delivered another strong performance in 2023 thanks to our diverse portfolio across markets and species and our dedicated colleagues,” said Kristin Peck, CEO of Zoetis. “We grew revenue 7% operationally, driven by our innovative companion animal franchises across pain, dermatology and parasiticides. We also grew our adjusted net income 7% operationally, while continuing to support investments in R&D, supply chain, and commercial excellence capabilities that will drive our next phase of growth.”